Amylyx Pharmaceuticals Stock Forecast
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AMLX analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$42.36+54.43%
- Strong buy 0
- Buy 11
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Amylyx Pharmaceuticals (2026-10-07), 11 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $42.36, with a high estimate of $57.00 and a low estimate of $20.00. The average target implies upside of 54.4% from the current price of $27.43.
The spread between the highest and lowest targets is 185.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AMLX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 11 | 92% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $20.00 | -27.09% |
| Average target | $42.36 | +54.43% |
| High target | $57.00 | +107.80% |